WOLVERINE (60 capsules 500mcg)
BPC-157 and TB-500 work. The delivery method is what fails.
Injectable peptides achieve systemic concentrations that produce measurable tissue repair. But $500+ monthly costs, daily sterility protocols, and needle logistics are not a sustainable protocol. Oral peptides get destroyed in digestion before they reach the blood. Wolverine solves both problems.
Gut-axis signaling
The Wolverine Bio-Matrix is a peptide-dense yeast hydrolysate containing low-molecular-weight fragments. These interact directly with the gastric lining — the primary site where your body produces its own repair signals — and modulate the local VEGF pathway, activating systemic recovery from the gut up.
Substrate loading
A concentrated substrate blueprint containing the exact amino acid sequences found in BPC-157 and TB-500: Proline, Glycine, Serine. Reduces the metabolic cost of tissue repair and accelerates the shift from inflammation to remodeling.
PepT1 transporter hijacking
The Bio-Matrix protects short-chain bioactive peptides through stomach acid. Intact peptide chains reach the small intestine and hijack PepT1 transporters — specialized express lanes that carry dipeptides and tripeptides directly into systemic circulation.
Injectable BPC-157 and TB-500 achieve systemic concentrations through direct bloodstream delivery. Wolverine works differently — the Bio-Matrix activates your body's endogenous repair environment via the gut-VEGF pathway, the substrate blueprint loads the precise amino acid building blocks those pathways require, and the PepT1 system carries short-chain bioactive fragments into circulation intact. The mechanism is distinct. The outcome — optimized tissue repair signaling — is the goal of both approaches.
Most users report measurable improvement in training recovery within 2–3 weeks of consistent daily use. Tendon and ligament response takes longer — typically 4–8 weeks — because connective tissue has a slower biological timeline than muscle.
Yes. Wolverine targets tissue repair pathways; Agelytix targets NAD+ restoration and GHK-Cu signaling. They operate through distinct mechanisms with no overlap or contraindication.